Related Experiment Videos

The next generation of diabetic nephropathy therapies: an update

Mark E Williams1, Katherine R Tuttle

  • 1Joslin Diabetes Center, Boston, MA 02215, USA.

Advances in Chronic Kidney Disease
|April 12, 2005
PubMed

Insights

New therapies are being investigated to combat progressive diabetic kidney disease. Agents targeting advanced glycation end-products (AGEs) and protein kinase C beta (PKC-beta) show promise in early trials.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic kidney disease (DKD) remains a significant health concern, with many patients experiencing disease progression despite current treatments.
  • There is an urgent need for more effective therapeutic strategies to manage DKD and prevent its complications.

Purpose of the Study:

  • This review focuses on novel therapeutic agents currently under evaluation in clinical trials for diabetic kidney disease.
  • The aim is to present promising new treatments that could offer improved outcomes for patients with DKD.

Main Methods:

  • The review discusses agents like sulodexide, pyridoxamine, alagebrium, and ruboxistaurin.
  • Mechanisms of action include ameliorating glomerular basement membrane abnormalities, inhibiting advanced glycation end-product (AGE) formation, breaking AGE cross-links, and inhibiting protein kinase C beta (PKC-beta).
  • Experimental models and early-phase clinical trial data (Phase II) are considered.

Main Results:

  • Sulodexide demonstrated potential in preventing diabetic nephropathy in experimental models.
  • Pyridoxamine and alagebrium showed kidney protection in experimental models by targeting AGEs.
  • Ruboxistaurin prevented diabetic kidney disease in animal models by inhibiting PKC-beta.
  • Phase II studies indicated these agents are promising, showing reductions in albuminuria and preservation of kidney function.

Conclusions:

  • Novel agents targeting AGEs and PKC-beta pathways have shown promise in preclinical and early clinical studies for diabetic kidney disease.
  • Further Phase III trials are planned to confirm the efficacy of these agents in improving clinical outcomes, including mortality and cardiovascular events, beyond the current standard of care.

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetes Insipidus II: Pathophysiology01:22

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...